Demonstrating the safety profile of a new drug intervention is a pre-requisite for market access. Thomas will introduce the structure of Nordic health register data with a case on how a multi-country safety study was developed to support market access by including health economic aspects in the study design. The Nordic region is regarded as one of the most advanced places to develop and access high quality data, and studies in the Nordic region are a unique opportunity to generate high-quality evidence that can help pharma and medtech companies understand and demonstrate the value of their medicines to physicians, payers and patients in the region and beyond. The Nordic Evidence Leaders Forum is organised by NextLevel Life Sciences and will to take place 14th-15th of May.

Read more about the event here: